BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paulsen JS, Nance M, Kim JI, Carlozzi NE, Panegyres PK, Erwin C, Goh A, McCusker E, Williams JK. A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Prog Neurobiol 2013;110:2-28. [PMID: 24036231 DOI: 10.1016/j.pneurobio.2013.08.003] [Cited by in Crossref: 90] [Cited by in F6Publishing: 74] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Gautam A. Towards Modern-Age Advanced Sensors for the Management of Neurodegenerative Disorders: Current Status, Challenges and Prospects. ECS Sens Plus 2022;1:042401. [DOI: 10.1149/2754-2726/ac973e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dratch L, Mu W, Wood EM, Morgan B, Massimo L, Clyburn C, Bardakjian T, Grossman M, Irwin DJ, Cousins KA. Evaluation of an educational conference for persons affected by hereditary frontotemporal degeneration and amyotrophic lateral sclerosis. PEC Innovation 2022. [DOI: 10.1016/j.pecinn.2022.100108] [Reference Citation Analysis]
3 Carver RB, Fredheim NAG, Mowinckel AM, Ebmeier KP, Friedman BB, Rosness TA, Drevon CA, Suri S, Baaré WFC, Zsoldos E, Solé-padullés C, Bartrés-faz D, Ghisletta P, Nawijn L, Düzel S, Madsen KS, Fjell AM, Lindenberger U, Walhovd KB, Budin-ljøsne I. People's interest in brain health testing: Findings from an international, online cross-sectional survey. Front Public Health 2022;10:998302. [DOI: 10.3389/fpubh.2022.998302] [Reference Citation Analysis]
4 Cook AA, Jayabal S, Sheng J, Fields E, Leung TCS, Quilez S, Mcnicholas E, Lau L, Huang S, Watt AJ. Activation of TrkB-Akt signaling rescues deficits in a mouse model of SCA6. Sci Adv 2022;8:eabh3260. [DOI: 10.1126/sciadv.abh3260] [Reference Citation Analysis]
5 Rodríguez-agudelo Y, Chávez-oliveros M, Ochoa-morales A, Martínez-ruano L, Camacho-molina A, Paz-rodríguez F. Psychological discomfort in carriers and non-carriers of the Huntington disease mutation and its relationship with disease burden. Neurología (English Edition) 2022. [DOI: 10.1016/j.nrleng.2022.06.005] [Reference Citation Analysis]
6 Birolini G, Valenza M, Ottonelli I, Talpo F, Minoli L, Cappelleri A, Bombaci M, Caccia C, Leoni V, Passoni A, Favagrossa M, Nucera MR, Colombo L, Paltrinieri S, Bagnati R, Duskey JT, Caraffi R, Vandelli MA, Taroni F, Salmona M, Scanziani E, Biella G, Ruozi B, Tosi G, Cattaneo E. Cholesterol-laden brain-permeable nanoparticles support long-lasting cognitive recovery and motor amelioration in the slow-progressing zQ175DN mouse model of Huntington’s Disease.. [DOI: 10.1101/2022.08.26.505426] [Reference Citation Analysis]
7 Reyes RG, Martinez Montes E. Modeling neural activity in neurodegenerative diseases through a neural field model with variable density of neurons.. [DOI: 10.1101/2022.08.23.504980] [Reference Citation Analysis]
8 Rodríguez-agudelo Y, Chávez-oliveros M, Ochoa-morales A, Martínez-ruano L, Camacho-molina A, Paz-rodríguez F. Malestar psicológico en portadores y no portadores de la mutación causante de enfermedad de Huntington y su relación con la carga de la enfermedad. Neurología 2022. [DOI: 10.1016/j.nrl.2022.06.007] [Reference Citation Analysis]
9 Goldman JS, Vallabh SM. Genetic counseling for prion disease: Updates and best practices. Genet Med 2022:S1098-3600(22)00812-7. [PMID: 35819418 DOI: 10.1016/j.gim.2022.06.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Erbguth F, Lorenzl S, Röther J, Rogge A. Bedeutung des assistierten Suizids für die Neurologie nach dem Urteil des Bundesverfassungsgerichts 2020. DGNeurologie 2022;5:179-188. [DOI: 10.1007/s42451-022-00431-0] [Reference Citation Analysis]
11 Karagianis JL. Re: Risk Disclosure in Prodromal Parkinson's Disease. Mov Disord 2022. [PMID: 35481903 DOI: 10.1002/mds.29038] [Reference Citation Analysis]
12 Makarious MB, Leonard HL, Vitale D, Iwaki H, Sargent L, Dadu A, Violich I, Hutchins E, Saffo D, Bandres-Ciga S, Kim JJ, Song Y, Maleknia M, Bookman M, Nojopranoto W, Campbell RH, Hashemi SH, Botia JA, Carter JF, Craig DW, Van Keuren-Jensen K, Morris HR, Hardy JA, Blauwendraat C, Singleton AB, Faghri F, Nalls MA. Multi-modality machine learning predicting Parkinson's disease. NPJ Parkinsons Dis 2022;8:35. [PMID: 35365675 DOI: 10.1038/s41531-022-00288-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Galluzzi S, Mega A, Di Fede G, Muscio C, Fascendini S, Benussi L, Tagliavini F, Frisoni GB, Di Maria E; Italian-DIAfN Working Group. Psychological Impact of Predictive Genetic Testing for Inherited Alzheimer Disease and Frontotemporal Dementia: The IT-DIAfN Protocol. Alzheimer Dis Assoc Disord 2022;36:118-24. [PMID: 35293381 DOI: 10.1097/WAD.0000000000000494] [Reference Citation Analysis]
14 van der Schaar J, Visser LNC, Bouwman FH, Ket JCF, Scheltens P, Bredenoord AL, van der Flier WM. Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review. Alzheimers Res Ther 2022;14:31. [PMID: 35144684 DOI: 10.1186/s13195-022-00971-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
15 Handels RL, Zwan MD, Pelkmans W, Biessels GJ, van Domburg P, Hoff E, Roks G, Schoonenboom N, Verweij N, van Berckel BN, van der Flier WM, Verhey F, Scheltens P, Bouwman FH. Added diagnostic accuracy after [18F]flutemetamol PET scanning in young patients with dementia in an academic memory clinic setting.. [DOI: 10.1101/2021.11.30.21266815] [Reference Citation Analysis]
16 Vasconcelos B, Fiedler P, Machts R, Haueisen J, Fonseca C. The Arch Electrode: A Novel Dry Electrode Concept for Improved Wearing Comfort. Front Neurosci 2021;15:748100. [PMID: 34733134 DOI: 10.3389/fnins.2021.748100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Incorvaia AD. Early Detection of Alzheimer's Disease Benefits Research, Quality of Life, and End-of-Life Planning. AJOB Neurosci 2021;12:243-4. [PMID: 34704912 DOI: 10.1080/21507740.2021.1941404] [Reference Citation Analysis]
18 Panegyres PK. The Clinical Spectrum of Young Onset Dementia Points to Its Stochastic Origins. J Alzheimers Dis Rep 2021;5:663-79. [PMID: 34632303 DOI: 10.3233/ADR-210309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 van der Schaar J, Visser LN, Bouwman FH, Scheltens P, Bredenoord AL, van der Flier WM. Considerations regarding a diagnosis of Alzheimer’s Disease before dementia: a systematic review.. [DOI: 10.1101/2021.09.16.21263690] [Reference Citation Analysis]
20 Mozersky J, Hartz S, Linnenbringer E, Levin L, Streitz M, Stock K, Moulder K, Morris JC. Communicating 5-Year Risk of Alzheimer's Disease Dementia: Development and Evaluation of Materials that Incorporate Multiple Genetic and Biomarker Research Results. J Alzheimers Dis 2021;79:559-72. [PMID: 33337371 DOI: 10.3233/JAD-200993] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
21 Schaeffer E, Toedt I, Köhler S, Rogge A, Berg D. Risk Disclosure in Prodromal Parkinson's Disease. Mov Disord 2021. [PMID: 34351002 DOI: 10.1002/mds.28723] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
22 Wong B, Lucente D, Krivensky S, Krahn E, Karlawish J, Dickerson BC. Knowledge assessment and psychological impact of genetic counseling in people at risk for familial FTD. Alzheimers Dement (Amst) 2021;13:e12225. [PMID: 34337135 DOI: 10.1002/dad2.12225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Mahmood S, Law S, Bombard Y. "I have to start learning how to live with becoming sick": A scoping review of the lived experiences of people with Huntington's disease. Clin Genet 2021. [PMID: 34216010 DOI: 10.1111/cge.14024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Linden I, Wolfs C, Perry M, Metsemakers J, van der Weijden T, de Vugt M, Verhey FR, Handels R, Olde Rikkert M, Dirksen C, Ponds RWHM. Implementation of a diagnostic decision aid for people with memory complaints and their general practitioners: a protocol of a before and after pilot trial. BMJ Open 2021;11:e049322. [PMID: 34135053 DOI: 10.1136/bmjopen-2021-049322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Puckett Y, Mallorga-Hernández A, Montaño AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. Orphanet J Rare Dis 2021;16:241. [PMID: 34051828 DOI: 10.1186/s13023-021-01880-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
26 Lake J, Storm CS, Makarious MB, Bandres-Ciga S. Genetic and Transcriptomic Biomarkers in Neurodegenerative Diseases: Current Situation and the Road Ahead. Cells 2021;10:1030. [PMID: 33925602 DOI: 10.3390/cells10051030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
27 Rostamzadeh A, Schwegler C, Gil-navarro S, Rosende-roca M, Romotzky V, Ortega G, Canabate P, Moreno M, Schmitz-luhn B, Boada M, Jessen F, Woopen C. Biomarker-Based Risk Prediction of Alzheimer’s Disease Dementia in Mild Cognitive Impairment: Psychosocial, Ethical, and Legal Aspects: Study Protocol of the PreDADQoL Project. JAD 2021;80:601-17. [DOI: 10.3233/jad-200484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Liu X, Yuan Q, Li GX, Jia CC, Liu JY, Yang YQ, Wang XY, Hou Y, Wang B. Regulation of Superoxide by BAP31 through Its Effect on p22phox and Keap1/Nrf2/HO-1 Signaling Pathway in Microglia. Oxid Med Cell Longev 2021;2021:1457089. [PMID: 33777312 DOI: 10.1155/2021/1457089] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Ursin F, Timmermann C, Steger F. Ethical Implications of Alzheimer's Disease Prediction in Asymptomatic Individuals through Artificial Intelligence. Diagnostics (Basel) 2021;11:440. [PMID: 33806501 DOI: 10.3390/diagnostics11030440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Cook AA, Jayabal S, Sheng J, Fields E, Leung TCS, Quilez S, Mcnicholas E, Lau L, Watt AJ. Restoration of BDNF-TrkB signaling rescues deficits in a mouse model of SCA6.. [DOI: 10.1101/2021.02.21.432180] [Reference Citation Analysis]
31 Talebi M, Talebi M, Kakouri E, Farkhondeh T, Pourbagher-Shahri AM, Tarantilis PA, Samarghandian S. Tantalizing role of p53 molecular pathways and its coherent medications in neurodegenerative diseases. Int J Biol Macromol 2021;172:93-103. [PMID: 33440210 DOI: 10.1016/j.ijbiomac.2021.01.042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
32 Halpin M. Secondary Symptoms Dementia: Huntington Disease Dementia. The Palgrave Encyclopedia of Critical Perspectives on Mental Health 2021. [DOI: 10.1007/978-3-030-12852-4_5-1] [Reference Citation Analysis]
33 Goldman J, Xie S, Green D, Naini A, Mansukhani MM, Marder K. Predictive testing for neurodegenerative diseases in the age of next-generation sequencing. J Genet Couns 2020. [PMID: 33090625 DOI: 10.1002/jgc4.1342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
34 Dommershuijsen LJ, Darweesh SKL, Luik AI, Kieboom BCT, Koudstaal PJ, Boon AJW, Ikram MA, Ikram MK, Bunnik EM. Ethical Considerations in Screening for Rapid Eye Movement Sleep Behavior Disorder in the General Population. Mov Disord 2020;35:1939-44. [PMID: 32930445 DOI: 10.1002/mds.28262] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
35 Birmann PT, Casaril AM, Hartwig D, Jacob RG, Seixas FK, Collares T, Savegnago L. A novel pyrazole-containing selenium compound modulates the oxidative and nitrergic pathways to reverse the depression-pain syndrome in mice. Brain Research 2020;1741:146880. [DOI: 10.1016/j.brainres.2020.146880] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
36 Morganti F, Palena N, Savoldelli P, Greco A. Take the First-Person Perspective to Become Dementia-Friendly: The Use of 360° Video for Experiencing Everyday-Life Challenges With Cognitive Decline. Front Psychol 2020;11:1117. [PMID: 32695039 DOI: 10.3389/fpsyg.2020.01117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Schaeffer E, Rogge A, Nieding K, Helmker V, Letsch C, Hauptmann B, Berg D. Patients' views on the ethical challenges of early Parkinson disease detection. Neurology 2020;94:e2037-44. [DOI: 10.1212/wnl.0000000000009400] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
38 Halpin MA. Into the Prodrome: Diagnosis, Disadvantage, and Biomedical Ambiguity. Society and Mental Health 2021;11:38-53. [DOI: 10.1177/2156869320912456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Bonvicini C, Scassellati C, Benussi L, Di Maria E, Maj C, Ciani M, Fostinelli S, Mega A, Bocchetta M, Lanzi G, Giacopuzzi E, Ferraboli S, Pievani M, Fedi V, Defanti CA, Giliani S, Frisoni GB, Ghidoni R, Gennarelli M; Alzheimer’s Disease Neuroimaging Initiative. Next Generation Sequencing Analysis in Early Onset Dementia Patients. J Alzheimers Dis 2019;67:243-56. [PMID: 30530974 DOI: 10.3233/JAD-180482] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
40 Boileau NR, Paulsen JS, Ready RE, Hahn EA, Lai JS, Carlozzi NE. Understanding domains that influence perceived stigma in individuals with Huntington disease. Rehabil Psychol 2020;65:113-21. [PMID: 31961169 DOI: 10.1037/rep0000311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Tuena C, Semonella M, Fernández-álvarez J, Colombo D, Cipresso P. Predictive Precision Medicine: Towards the Computational Challenge. P5 eHealth: An Agenda for the Health Technologies of the Future 2020. [DOI: 10.1007/978-3-030-27994-3_5] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
42 Seyfizadeh N, Seyfizadeh N, Borzouisileh S, Elahimanesh F, Hosseini V, Nouri M. Exosome-mediated therapeutic delivery: A new horizon for human neurodegenerative disorders’ treatment (with a focus on siRNA delivery improvement). Process Biochemistry 2019;85:164-74. [DOI: 10.1016/j.procbio.2019.06.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
43 Schwartz M, Brandel JP, Babonneau ML, Boucher C, Schaerer E, Haik S, Laplanche JL, Gargiulo M, Durr A. Genetic Testing in Prion Disease: Psychological Consequences of the Decisions to Know or Not to Know. Front Genet 2019;10:895. [PMID: 31616476 DOI: 10.3389/fgene.2019.00895] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
44 Bahrami A, Barreto GE, Lombardi G, Pirro M, Sahebkar A. Emerging roles for high‐density lipoproteins in neurodegenerative disorders. BioFactors 2019;45:725-39. [DOI: 10.1002/biof.1541] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
45 Galts CP, Bettio LE, Jewett DC, Yang CC, Brocardo PS, Rodrigues ALS, Thacker JS, Gil-mohapel J. Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neuroscience & Biobehavioral Reviews 2019;102:56-84. [DOI: 10.1016/j.neubiorev.2019.04.002] [Cited by in Crossref: 99] [Cited by in F6Publishing: 71] [Article Influence: 33.0] [Reference Citation Analysis]
46 Ahlgrim NS, Garza K, Hoffman C, Rommelfanger KS. Prodromes and Preclinical Detection of Brain Diseases: Surveying the Ethical Landscape of Predicting Brain Health. eNeuro 2019;6:ENEURO. [PMID: 31221862 DOI: 10.1523/ENEURO.0439-18.2019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
47 Sng WT, Yeo SN, Lin BX, Lee TS. Impacts of apolipoprotein E disclosure on healthy Asian older adults: a cohort study. Int Psychogeriatr 2019;31:1499-507. [PMID: 30894233 DOI: 10.1017/S1041610218002089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
48 Sherman CW, Iyer R, Abler V, Antonelli A, Carlozzi NE. Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians. Neuropsychol Rehabil 2020;30:1150-68. [PMID: 30849283 DOI: 10.1080/09602011.2018.1564675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
49 Park CH, Yang P, Yoon YS, Ra J. Study on the safety of Polygala tenuifolia Willdenow root extract powder (BT-11) in young person aged from 9 to 19 years old. Journal of Ethnopharmacology 2019;232:119-29. [DOI: 10.1016/j.jep.2018.12.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
50 Biesecker BB, Tibben A. Summary of Key Areas for Research. Clinical Genome Sequencing 2019. [DOI: 10.1016/b978-0-12-813335-4.00013-1] [Reference Citation Analysis]
51 Biesecker BB, Tibben A, Vos J. Uncertainties in Genome Sequencing. Clinical Genome Sequencing 2019. [DOI: 10.1016/b978-0-12-813335-4.00005-2] [Reference Citation Analysis]
52 Tibben A, Biesecker BB. Genetic Testing Expanded. Clinical Genome Sequencing 2019. [DOI: 10.1016/b978-0-12-813335-4.00001-5] [Reference Citation Analysis]
53 Manrique de Lara A, Soto-Gómez L, Núñez-Acosta E, Saruwatari-Zavala G, Rentería ME. Ethical issues in susceptibility genetic testing for late-onset neurodegenerative diseases. Am J Med Genet B Neuropsychiatr Genet 2019;180:609-21. [PMID: 30525300 DOI: 10.1002/ajmg.b.32699] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
54 Prince AER, Berkman BE. Reconceptualizing harms and benefits in the genomic age. Per Med 2018;15:419-28. [PMID: 30260295 DOI: 10.2217/pme-2018-0022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
55 Handels RLH, Wimo A, Dodel R, Kramberger MG, Visser PJ, Molinuevo JL, Verhey FRJ, Winblad B. Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. J Alzheimers Dis 2017;60:1477-87. [PMID: 29081416 DOI: 10.3233/JAD-170324] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
56 Paulsen JS, Miller AC, Hayes T, Shaw E. Cognitive and behavioral changes in Huntington disease before diagnosis. Handb Clin Neurol 2017;144:69-91. [PMID: 28947127 DOI: 10.1016/B978-0-12-801893-4.00006-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
57 Jia Z, Wei Y, Li X, Yang L, Liu H, Guo C, Zhang L, Li N, Guo S, Qian Y, Li Z. Exposure to Ambient Air Particles Increases the Risk of Mental Disorder: Findings from a Natural Experiment in Beijing. Int J Environ Res Public Health 2018;15:E160. [PMID: 29351245 DOI: 10.3390/ijerph15010160] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
58 Simmons Z. Genetic Testing of Presymptomatic Individuals at Risk for Progressive Myopathy. Continuum (Minneap Minn) 2016;22:2006-11. [PMID: 27922504 DOI: 10.1212/01.CON.0000511073.81209.24] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Hartzell JW, Geary R, Gyure K, Chivukula VR, Haut MW. Completed suicide in an autopsy-confirmed case of early onset Alzheimer's disease. Neurodegener Dis Manag 2018;8:81-8. [PMID: 29319406 DOI: 10.2217/nmt-2017-0045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
60 Hostiuc S, Negoi I, Rusu MC, Hostiuc M. Stem Cell Therapies for Neurodegenerative Disorders: An Ethical Analysis. Clinical Ethics At the Crossroads of Genetic and Reproductive Technologies. Elsevier; 2018. pp. 205-28. [DOI: 10.1016/b978-0-12-813764-2.00010-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Kurz AF, Lautenschlager NT. The Ethics of Biomarker-Based Preclinical Diagnosis of Alzheimer’s Disease. Neuromethods 2018. [DOI: 10.1007/978-1-4939-7674-4_17] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Cohn-hokke PE, van Swieten JC, Pijnenburg YAL, Tibben A, Meijers-heijboer H, Kievit A. The Effect of Predictive Testing in Adult-Onset Neurodegenerative Diseases on Social and Personal Life. J Genet Counsel 2018;27:947-54. [DOI: 10.1007/s10897-017-0195-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
63 Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry 2018;19:244-328. [PMID: 29076399 DOI: 10.1080/15622975.2017.1375556] [Cited by in Crossref: 161] [Cited by in F6Publishing: 138] [Article Influence: 32.2] [Reference Citation Analysis]
64 Cao S, Du J, Hei Q. Lycium barbarum polysaccharide protects against neurotoxicity via the Nrf2-HO-1 pathway. Exp Ther Med 2017;14:4919-27. [PMID: 29201196 DOI: 10.3892/etm.2017.5127] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
65 McCusker EA, Loy CT. Huntington Disease: The Complexities of Making and Disclosing a Clinical Diagnosis After Premanifest Genetic Testing. Tremor Other Hyperkinet Mov (N Y) 2017;7:467. [PMID: 28975045 DOI: 10.7916/D8PK0TDD] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
66 Liao L, Zhang X, Li J, Zhang Z, Yang C, Rao C, Zhou C, Zeng L, Zhao L, Fang L, Yang D, Xie P. Pioglitazone attenuates lipopolysaccharide-induced depression-like behaviors, modulates NF-κB/IL-6/STAT3, CREB/BDNF pathways and central serotonergic neurotransmission in mice. International Immunopharmacology 2017;49:178-86. [DOI: 10.1016/j.intimp.2017.05.036] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
67 Crook A, Williams K, Adams L, Blair I, Rowe DB. Predictive genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling considerations. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:475-85. [PMID: 28585888 DOI: 10.1080/21678421.2017.1332079] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
68 Ibisler A, Ocklenburg S, Stemmler S, Arning L, Epplen JT, Saft C, Hoffjan S. Prospective Evaluation of Predictive DNA Testing for Huntington's Disease in a Large German Center. J Genet Couns 2017;26:1029-40. [PMID: 28361381 DOI: 10.1007/s10897-017-0085-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
69 Halpin M. Science and Suffering: Genetics and the Lived Experience of Illness. Social Problems 2018;65:360-76. [DOI: 10.1093/socpro/spw057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
70 Wang R, Chen Z, Fu Y, Wei X, Liao J, Liu X, He B, Xu Y, Zou J, Yang X, Weng R, Tan S, McElroy C, Jin K, Wang Q. Plasma Cystatin C and High-Density Lipoprotein Are Important Biomarkers of Alzheimer's Disease and Vascular Dementia: A Cross-Sectional Study. Front Aging Neurosci 2017;9:26. [PMID: 28223934 DOI: 10.3389/fnagi.2017.00026] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
71 Low JA, Ho E. Managing Ethical Dilemmas in End-Stage Neurodegenerative Diseases. Geriatrics (Basel) 2017;2:E8. [PMID: 31011018 DOI: 10.3390/geriatrics2010008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
72 Henn W. Neurogenetik. Angewandte Ethik in der Neuromedizin 2017. [DOI: 10.1007/978-3-662-49916-0_5] [Reference Citation Analysis]
73 Groves M. The highly anxious individual presenting for Huntington disease-predictive genetic testing: the psychiatrist's role in assessment and counseling. Huntington Disease. Elsevier; 2017. pp. 99-105. [DOI: 10.1016/b978-0-12-801893-4.00008-0] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
74 Goldman JS, Huey ED, Thorne DZ. The Confluence of Psychiatric Symptoms and Neurodegenerative Disease: Impact on Genetic Counseling. J Genet Couns 2017;26:435-41. [PMID: 28013481 DOI: 10.1007/s10897-016-0056-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
75 Carlozzi NE, Schilling SG, Lai JS, Paulsen JS, Hahn EA, Perlmutter JS, Ross CA, Downing NR, Kratz AL, McCormack MK, Nance MA, Quaid KA, Stout JC, Gershon RC, Ready RE, Miner JA, Barton SK, Perlman SL, Rao SM, Frank S, Shoulson I, Marin H, Geschwind MD, Dayalu P, Goodnight SM, Cella D. HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Qual Life Res 2016;25:2441-55. [PMID: 27522213 DOI: 10.1007/s11136-016-1386-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
76 Carradori D, Gaudin A, Brambilla D, Andrieux K. Application of Nanomedicine to the CNS Diseases. Int Rev Neurobiol 2016;130:73-113. [PMID: 27678175 DOI: 10.1016/bs.irn.2016.06.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
77 Fjermestad KW, Kanavin ØJ, Næss EE, Hoxmark LB, Hummelvoll G. Health survey of adults with hereditary spastic paraparesis compared to population study controls. Orphanet J Rare Dis 2016;11:98. [PMID: 27412159 DOI: 10.1186/s13023-016-0469-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
78 Chekani F, Bali V, Aparasu RR. Quality of life of patients with Parkinson's disease and neurodegenerative dementia: A nationally representative study. Research in Social and Administrative Pharmacy 2016;12:604-13. [DOI: 10.1016/j.sapharm.2015.09.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
79 Wilkinson B, Arora KS. A Systematic Review on Confidentiality, Disclosure, and Stigma in the United States: Lessons for HIV Care in Pregnancy From Reproductive Genetics. New Bioeth 2015;21:142-54. [PMID: 27124962 DOI: 10.1179/2050287715z.00000000067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
80 Carlozzi NE, Miciura A, Migliore N, Dayalu P. Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review. J Huntingtons Dis 2014;3:233-52. [PMID: 25300328 DOI: 10.3233/JHD-140115] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
81 Erwin C. Ethical Issues Raised by Epigenetic Testing for Alcohol, Tobacco, and Cannabis. Behav Sci Law 2015;33:662-74. [PMID: 26358643 DOI: 10.1002/bsl.2204] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
82 Guan D, Su Y, Li Y, Wu C, Meng Y, Peng X, Cui Y. Tetramethylpyrazine inhibits CoCl 2 -induced neurotoxicity through enhancement of Nrf2/GCLc/GSH and suppression of HIF1α/NOX2/ROS pathways. J Neurochem 2015;134:551-65. [DOI: 10.1111/jnc.13161] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
83 Goldman JS. Genetic Testing and Counseling in the Diagnosis and Management of Young-Onset Dementias. Psychiatric Clinics of North America 2015;38:295-308. [DOI: 10.1016/j.psc.2015.01.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
84 Acquarone M, de Melo TM, Meireles F, Brito-Moreira J, Oliveira G, Ferreira ST, Castro NG, Tovar-Moll F, Houzel JC, Rehen SK. Mitomycin-treated undifferentiated embryonic stem cells as a safe and effective therapeutic strategy in a mouse model of Parkinson's disease. Front Cell Neurosci 2015;9:97. [PMID: 25904842 DOI: 10.3389/fncel.2015.00097] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
85 Haile Y, Nakhaei-Nejad M, Boakye PA, Baker G, Smith PA, Murray AG, Giuliani F, Jahroudi N. Reprogramming of HUVECs into induced pluripotent stem cells (HiPSCs), generation and characterization of HiPSC-derived neurons and astrocytes. PLoS One 2015;10:e0119617. [PMID: 25789622 DOI: 10.1371/journal.pone.0119617] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
86 Kim SY, Karlawish J, Berkman BE. Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. Neurology 2015;84:1488-94. [PMID: 25762713 DOI: 10.1212/WNL.0000000000001451] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
87 Surampalli A, Khare M, Kubrussi G, Wencel M, Tanaja J, Donkervoort S, Osann K, Simon M, Wallace D, Smith C, M McInerney-Leo A, Kimonis V. Psychological Impact of Predictive Genetic Testing in VCP Inclusion Body Myopathy, Paget Disease of Bone and Frontotemporal Dementia. J Genet Couns 2015;24:842-50. [PMID: 25716352 DOI: 10.1007/s10897-015-9819-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
88 O'Neill SC, Tercyak KP, Baytop C, Hensley Alford S, McBride CM. A new approach to assessing affect and the emotional implications of personal genomic testing for common disease risk. Public Health Genomics 2015;18:104-12. [PMID: 25612474 DOI: 10.1159/000370101] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
89 McCusker E, Loy CT. The many facets of unawareness in huntington disease. Tremor Other Hyperkinet Mov (N Y) 2014;4:257. [PMID: 25411649 DOI: 10.7916/D8FJ2FD3] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
90 Friess MR, Marino BS, Cassedy A, Wilmot I, Jefferies JL, Lorts A. Health-related quality of life assessment in children followed in a cardiomyopathy clinic. Pediatr Cardiol 2015;36:516-23. [PMID: 25287220 DOI: 10.1007/s00246-014-1042-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
91 Jarmolowicz AI, Chen HY, Panegyres PK. The patterns of inheritance in early-onset dementia: Alzheimer's disease and frontotemporal dementia. Am J Alzheimers Dis Other Demen 2015;30:299-306. [PMID: 25147204 DOI: 10.1177/1533317514545825] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
92 Paulsen JS, Long JD. Onset of Huntington's disease: can it be purely cognitive? Mov Disord 2014;29:1342-50. [PMID: 25142616 DOI: 10.1002/mds.25997] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
93 Gourna EG, Armstrong N, Wallace SE. Incidental findings from clinical sequencing in Greece: reporting experts' attitudes. J Community Genet 2014;5:383-93. [PMID: 25048384 DOI: 10.1007/s12687-014-0194-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
94 Vinther-Jensen T, Larsen IU, Hjermind LE, Budtz-Jørgensen E, Nielsen TT, Nørremølle A, Nielsen JE, Vogel A. A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease. Orphanet J Rare Dis 2014;9:114. [PMID: 25026978 DOI: 10.1186/s13023-014-0114-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
95 Victorson D, Carlozzi NE, Frank S, Beaumont JL, Cheng W, Gorin B, Duh MS, Samuelson D, Tulsky D, Gutierrez S, Nowinski CJ, Mueller A, Shen V, Sung V. Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives. Tremor Other Hyperkinet Mov (N Y) 2014;4:224. [PMID: 24757585 DOI: 10.7916/D8JW8BWS] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
96 Carlozzi NE, Victorson D, Sung V, Beaumont JL, Cheng W, Gorin B, Duh MS, Samuelson D, Tulsky D, Gutierrez S, Nowinski CJ, Mueller A, Shen V, Frank S. HD-PRO-TRIAD™ Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease. Tremor Other Hyperkinet Mov (N Y) 2014;4:223. [PMID: 24761312 DOI: 10.7916/D8PN93NZ] [Cited by in F6Publishing: 11] [Reference Citation Analysis]